Cargando…

Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study

BACKGROUND: Little is known about the benefits of adjuvant endocrine therapy (ET) in low ER-positive breast cancer (1%–10%) patients. We analyzed the association between ET and breast cancer-specific survival (BCSS) in these patients with respect to the regimen and the duration of ET. METHODS: Patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Yuxin, Yang, Libo, Wu, Yanqi, Zheng, Hong, Gou, Qiheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551143/ https://www.ncbi.nlm.nih.gov/pubmed/36209701 http://dx.doi.org/10.1016/j.breast.2022.09.008

Ejemplares similares

Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer
por: Luo, Chuanxu, et al.
Publicado: (2022)

Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort
por: Cai, Yu‐Wen, et al.
Publicado: (2022)

Prognosis and Treatment of Metastatic Breast Cancer From A Real-World Scenario in China: A Retrospective Cohort Study
por: Xie, Yuxin, et al.
Publicado: (2022)

Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer
por: Xia, Song, et al.
Publicado: (2022)

microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
por: Howard, Erin W., et al.
Publicado: (2018)

Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor–Positive Early Breast Cancer
por: Cheung, Yee-Ming, et al.
Publicado: (2019)

Corrigendum: Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009)

KIF20A is a Prognostic Marker for Female Patients with Estrogen Receptor-Positive Breast Cancer and Receiving Tamoxifen as Adjuvant Endocrine Therapy
por: Huang, Xuchen, et al.
Publicado: (2023)

ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers
por: Nath, Aritro, et al.
Publicado: (2022)

Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients
por: Ahn, Jee Hyun, et al.
Publicado: (2021)

The role of BRCA status on prognosis in patients with triple-negative breast cancer
por: Xie, Yuxin, et al.
Publicado: (2017)

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
por: Iwata, Hiroji, et al.
Publicado: (2023)

Review of bone health in women with estrogen receptor–positive breast cancer receiving endocrine therapy
por: Malagrinò, Matteo, et al.
Publicado: (2023)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
por: Long, Mengping, et al.
Publicado: (2022)

Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability
por: Jeffreys, Sarah A., et al.
Publicado: (2020)

Role of estrogen receptor coregulators in endocrine resistant breast cancer
por: Altwegg, Kristin A., et al.
Publicado: (2021)

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
por: Sasada, Shinsuke, et al.
Publicado: (2023)

ESR1 alterations and metastasis in estrogen receptor positive breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2019)

The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration
por: Djahansouzi, Sirus, et al.
Publicado: (2021)

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
por: Verma, S., et al.
Publicado: (2009)

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
por: Ellis, Matthew J., et al.
Publicado: (2008)

Endocrine sensitivity of estrogen receptor‐positive breast cancer is negatively correlated with aspartate‐β‐hydroxylase expression
por: Shimoda, Masafumi, et al.
Publicado: (2017)

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
por: Xia, Youli, et al.
Publicado: (2022)

PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer
por: Rees, Michael, et al.
Publicado: (2020)

Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy
por: Kawiak, Anna, et al.
Publicado: (2022)

Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor–positive breast cancer
por: Chen, Weilin, et al.
Publicado: (2023)

Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience
por: Levy, Julia, et al.
Publicado: (2022)

Editorial: Estrogen receptors in endocrine disorders
por: Filardi, Tiziana, et al.
Publicado: (2023)

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)

ADAMTS6 suppresses tumor progression via the ERK signaling pathway and serves as a prognostic marker in human breast cancer
por: Xie, Yuxin, et al.
Publicado: (2016)

Characteristics and Prognosis of Estrogen Receptor Low-Positive Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2022)

Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2015)

A novel oncogenic enhancer of estrogen receptor-positive breast cancer
por: Bao, Chunjie, et al.
Publicado: (2022)

Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials
por: Hu, Qiancheng, et al.
Publicado: (2023)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
por: Sanchez, Cesar G, et al.
Publicado: (2011)

Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?
por: Haricharan, Svasti, et al.
Publicado: (2017)

An estrogen receptor (ER)‐related signature in predicting prognosis of ER‐positive breast cancer following endocrine treatment
por: Tang, Jianing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3cfncunut9hiogdm90f5vo8e1a